Condition

Treatment-resistant Schizophrenia

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 23 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials23
Recruiting4
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

23 shown
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant SchizophreniaNCT07184619 · 2026-01-23
RECRUITING
Cognitive Behavioral Therapy for Sleep and Circadian Disturbances (CBT-I) in Treatment-Resistant SchizophreniaNCT06749444 · 2024-11-28
RECRUITING
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory HallucinationsNCT05299749 · 2022-03-01
RECRUITING
Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.NCT05074732 · 2019-12-01
RECRUITING
Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant SchizophreniaNCT05259306 · 2027-06-01
SUSPENDED
Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant Schizophrenia: An Exploratory Study.NCT07773831 · 2026-08-01
NOT_YET_RECRUITING
The Characteristics of Treatment Resistant Schizophrenia From the Illness OnsetNCT06128408 · 2023-12-01
UNKNOWN
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology AnalysisNCT06060886 · 2023-11-01
UNKNOWN
Deep Brain Stimulation Recovery in Treatment-Resistant SchizophreniaNCT05337904 · 2023-09-01
ACTIVE_NOT_RECRUITING
An Exploratory Analysis of Immune and Inflammatory Response Associated With ClozapineNCT05741502 · 2023-08-16
TERMINATED
Deep Brain Stimulation in Treatment Resistant SchizophreniaNCT02361554 · 2023-03-01
TERMINATED
The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant SchizophreniaNCT06270108 · 2022-11-14
UNKNOWN
Hippocampus DBS in Treatment-resistant SchizophreniaNCT05694000 · 2022-11-01
UNKNOWN
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant SchizophreniaNCT04528095 · 2020-12-01
UNKNOWN
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)NCT03983018 · 2019-08-07
COMPLETED
Comparaison of Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory HallucinationsNCT04054778 · 2019-04-01
UNKNOWN
Telmisartan Pilot Study on Treatment Resistant SchizophreniaNCT03868839 · 2019-02-01
TERMINATED
Neural Biomarkers of Clozapine ResponseNCT03076346 · 2017-09-01
COMPLETED
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant SchizophreniaNCT03230864 · 2017-07-20
TERMINATED
Avatar Therapy in Comparison to Cognitive Behavioral Therapy for Treatment-resistant SchizophreniaNCT03585127 · 2017-03-01
COMPLETED
Virtual Reality Therapy for Treatment-resistant Auditory Hallucinations in SchizophreniaNCT03148639 · 2015-09-01
COMPLETED
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of CareNCT01431326 · 2011-11-01
COMPLETED
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic PatientsNCT01105481 · 2006-05-01
COMPLETED

Common interventions

Leading sponsors

Trial status mix

COMPLETED6
UNKNOWN6
RECRUITING4
TERMINATED4
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
SUSPENDED1

Phase mix

NA10
PHASE33
PHASE43
PHASE22
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.